C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib

Tsuguru Hayashi, Michihiko Shibata, Shinji Oe, Koichiro Miyagawa, Yuichi Honma and Masaru Harada

PLOS ONE, 2020, vol. 15, issue 12, 1-14

Abstract: Background and aim: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse events. This study aimed to identify predicting factors to select patients likely to benefit from lenvatinib treatment. Methods: We retrospectively analyzed 53 patients who were treated with lenvatinib for unresectable HCC. They were divided to two groups; low C-reactive protein (CRP) group with pretreatment serum CRP level

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244370 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 44370&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0244370

DOI: 10.1371/journal.pone.0244370

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().